IMUX — IMMUNIC, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1280776 ·
Last close
$7.56
Market Cap
$103.15M
52W High
$17.43
52W Low
$5.06
ADV30
415,192
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -35,327,000 | -34,099,000 | 159,169,000 | 155,098,000 | 31,588,000 |
| Mar 2026 | 0 | — | -33,235,000 | -32,588,000 | 189,742,000 | 186,629,000 | 38,509,000 |
| Dec 2025 | 0 | — | -23,327,000 | -19,300,000 | 24,052,000 | 15,483,000 | 30,725,000 |
| Sep 2025 | 0 | — | -25,993,000 | -25,579,000 | 40,704,000 | 35,132,000 | 30,205,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-81,331,000
Investing CF
$-116,000
Financing CF
$65,577,000
CapEx
$-116,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.89
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-641,159,000
Inventory
—
Receivables
$354,000
ST Investments
—
EBIT TTM
$-109,638,000
Pretax Income TTM
$-104,287,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -103,228,000 | -97,172,000 | 24,052,000 | 30,725,000 | -6,673,000 | -85,806,000 |
| Dec 2024 | 0 | -98,052,000 | -100,507,000 | 40,868,000 | 22,439,000 | 18,429,000 | -84,766,000 |
| Dec 2023 | 0 | -99,223,000 | -93,612,000 | 54,299,000 | 25,368,000 | 28,931,000 | -70,828,000 |
| Dec 2022 | 0 | -86,518,000 | -120,407,000 | 127,753,000 | 14,069,000 | 113,684,000 | -65,144,000 |
TTM Snapshot
Revenues TTM
$1,617,000
NetIncome TTM
$-104,287,000
OpCashFlow TTM
—
Assets (Latest)
$189,742,000
Forward EPS
$-2.43
Max Pain — expiry 2027-01-15
max pain strike: $10.00 · spot: $8.52 · call oi: 732 · put oi: 645
Expected Move to 2027-01-15:
±$6.18
(72.48%) —
implied range
$2.35 –
$14.70
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AARD | Aardvark Therapeutics, Inc. | $103.08M | $4.71 | — |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $101.93M | $5.27 | — |
| CPIX | CUMBERLAND PHARMACEUTICALS INC | $104.58M | $6.98 | — |
| ANIX | Anixa Biosciences Inc | $101.16M | $2.91 | — |
| KZIA | KAZIA THERAPEUTICS LTD | $100.79M | $8.82 | — |
News headlines (Yahoo Finance, 1h cache)
Immunic to present four vidofludimus calcium abstracts at MSToronto2026
2026-10-07 15:04 · Yahoo
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
2026-10-07 12:00 · Yahoo
Immunic to host virtual relapsing MS R&D Day on September 9
2026-09-02 12:40 · Yahoo
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
2026-09-02 10:30 · Yahoo
Immunic Appoints Chitrang Davé as Chief Data and Digital Officer
2026-09-01 10:30 · Yahoo
Immunic advances MS drug toward key Phase 3 data, expects results by year-end
2026-08-11 12:36 · Yahoo
Immunic appoints Elena Ridloff to board of directors
2026-08-10 20:36 · Yahoo
Immunic Appoints Elena Ridloff to Board of Directors
2026-08-10 20:05 · Yahoo
Immunic CEO on Q2 progress and Phase 3 MS trial milestones
2026-08-10 19:07 · Yahoo
Immunic to Participate in Investor Conferences in July
2026-07-09 10:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.